Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.43 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.42 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7139373 | 0.83 | ALDH1A1 (0.48) | GAATDP1ALDH1A1 | |
| SCHEMBL21129122 | 0.80 | CYP1A2 (0.51) | CYP1A2GAACYP2C9PKMCYP2C19 | |
| SCHEMBL21276509 | 0.80 | CYP1A2 (0.51) | CYP1A2GAACYP2C9PKMCYP2C19 | |
| SCHEMBL21095850 | 0.80 | TDP1 (0.51) | CYP1A2GAACYP2C9PKMCYP2C19 | |
| SCHEMBL20045392 | 0.80 | CYP1A2 (0.51) | CYP1A2GAACYP2C9PKMCYP2C19 | |
| SCHEMBL17273947 | 0.80 | TDP1 (0.51) | CYP1A2GAACYP2C9PKMCYP2C19 | |
| SCHEMBL4741323 | 0.78 | SYK (0.43) | — | |
| SCHEMBL31043196 | 0.78 | SYK (0.43) | — | |
| SCHEMBL4262556 | 0.78 | CYP1A2 (0.77) | CYP1A2GAACYP2C9PKMCYP2C19 | |
| SCHEMBL9819072 | 0.77 | CYP1A2 (0.65) | CYP1A2GAACYP2C9PKMCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11730714-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2023-08-22 | — | — | US | disclosed |
| US-11730714-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2023-08-22 | — | — | US | disclosed |
| US-11147788-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2021-10-19 | — | — | US | disclosed |
| US-10934244-B2 | Compounds for use in treating neuromuscular disorders | NMD PHARMA A/S (DK) | 2021-03-02 | — | — | US | disclosed |
| US-10385028-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2019-08-20 | — | — | US | disclosed |
| US-20190183812-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA A/S (DK) | 2019-06-20 | — | — | US | disclosed |
| US-20190185437-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA APS (DK) | 2019-06-20 | — | — | US | disclosed |
| US-20190183834-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA A/S (DK) | 2019-06-20 | — | — | US | disclosed |
| US-20190183863-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA A/S (DK) | 2019-06-20 | — | — | US | disclosed |
| US-20190185409-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA APS (DK) | 2019-06-20 | — | — | US | disclosed |
| US-20190183833-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA APS | 2019-06-20 | — | — | US | disclosed |
| US-20180099920-A1 | COMPOUNDS FOR USE IN TREATING NEUROMUSCULAR DISORDERS | NMD PHARMA APS (DK) | 2018-04-12 | — | — | US | disclosed |
| US-20180099920-A1 | COMPOUNDS FOR USE IN TREATING NEUROMUSCULAR DISORDERS | NMD PHARMA APS (DK) | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11730714-B2 | Compounds for the treatment of neuromuscular disorders | RYR1, CACNB1, RYR2 | CYP1A2 4681/4885GAA 2463/4885CYP2C9 4788/4885 |
| US-10934244-B2 | Compounds for use in treating neuromuscular disorders | CPT1B, CLCN2, TNNC1 | CYP1A2 4779/4885GAA 352/4885CYP2C9 4866/4885 |
| US-20190183834-A1 | Compounds For The Treatment Of Neuromuscular Disorders | RYR1, CACNB1, RYR2 | CYP1A2 4681/4885GAA 2463/4885CYP2C9 4788/4885 |
| US-20190185409-A1 | Compounds For The Treatment Of Neuromuscular Disorders | CPT1B, CLCN2, CACNB1 | CYP1A2 3724/4885GAA 1056/4885CYP2C9 4031/4885 |
| US-20180099920-A1 | COMPOUNDS FOR USE IN TREATING NEUROMUSCULAR DISORDERS | CPT1B, CLCN2, TNNC1 | CYP1A2 4779/4885GAA 352/4885CYP2C9 4866/4885 |
| US-20190183812-A1 | Compounds For The Treatment Of Neuromuscular Disorders | RYR1, CACNB1, RYR2 | CYP1A2 4681/4885GAA 2463/4885CYP2C9 4788/4885 |
| US-11147788-B2 | Compounds for the treatment of neuromuscular disorders | RYR1, CACNB1, RYR2 | CYP1A2 4681/4885GAA 2463/4885CYP2C9 4788/4885 |
| US-10385028-B2 | Compounds for the treatment of neuromuscular disorders | RYR1, CACNB1, RYR2 | CYP1A2 4681/4885GAA 2463/4885CYP2C9 4788/4885 |
| US-20190183863-A1 | Compounds For The Treatment Of Neuromuscular Disorders | RYR1, CACNB1, RYR2 | CYP1A2 4681/4885GAA 2463/4885CYP2C9 4788/4885 |
| US-20190185437-A1 | Compounds For The Treatment Of Neuromuscular Disorders | CLCN2, SCN1B, CACNB1 | CYP1A2 4673/4885GAA 596/4885CYP2C9 4761/4885 |
| US-20190183833-A1 | Compounds For The Treatment Of Neuromuscular Disorders | RYR1, CACNB1, RYR2 | CYP1A2 4681/4885GAA 2463/4885CYP2C9 4788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.